Hypertrophic Cardiomyopathy

• EMA approval · 2026-04-16
  EMA Authorised: Myqorzo (aficamten) — Cytokinetics (Ireland) Limited

  The European Medicines Agency authorised Myqorzo (aficamten) for the treatment of hypertrophic cardiomyopathy.

• FDA approval · 2026-02-05
  FDA Approved: MYQORZO — Supplemental Application (Cytokinetics Inc.)

  FDA approved a supplemental application for MYQORZO (aficamten) from Cytokinetics Inc. This action authorizes changes associated with the dr…

• FDA approval · 2025-12-19
  FDA Approved: MYQORZO — Original Application (Cytokinetics Inc.)

  The FDA approved MYQORZO (aficamten) from Cytokinetics as an original-application approval for the treatment of symptomatic obstructive hype…

• EMA approval · 2025-10-23
  EMA Authorised: Camzyos (Mavacamten) — Bristol-Myers Squibb Pharma EEIG

  The European Medicines Agency authorised Camzyos (mavacamten) for hypertrophic cardiomyopathy, with Bristol-Myers Squibb Pharma EEIG as the …

• FDA approval · 2025-04-17
  FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

  The FDA approved a supplemental application for CAMZYOS (mavacamten) from Myokardia, Inc., marking an approved update to its labeling or ind…

• Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
• FDA approval · 2024-04-30
  FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

  The FDA approved a supplemental application for CAMZYOS (mavacamten) submitted by Myokardia, Inc., resulting in an approved modification to …

• FDA approval · 2023-12-19
  FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

  FDA approved a supplemental application for Camzyos (mavacamten) from Myokardia, Inc., advancing regulatory action related to the drug.

• FDA approval · 2023-06-15
  FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

  FDA approved a supplemental application for CAMZYOS (mavacamten) submitted by Myokardia, Inc. The action represents an additional approval r…

• FDA approval · 2023-01-13
  FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

  FDA approved a supplemental application for CAMZYOS (mavacamten) from Myokardia, Inc. The approval expands the drug’s indications for hypert…

• FDA approval · 2022-11-22
  FDA Approved: CAMZYOS — Supplemental Application (Myokardia, Inc.)

  FDA approved a supplemental application for CAMZYOS (mavacamten) from Myokardia, Inc., expanding/ updating its labeling. The action pertains…

• FDA approval · 2022-04-28
  FDA Approved: CAMZYOS — Original Application (Myokardia, Inc.)

  FDA approved CAMZYOS (mavacamten) from MyoKardia for adults with symptomatic obstructive hypertrophic cardiomyopathy, marking a new mechanis…